Embecta Corp. (EMBC)
| Market Cap | 1.54B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 57.80M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,163,941 |
| Open | 25.87 |
| Previous Close | 25.84 |
| Day's Range | 25.53 - 27.33 |
| 52-Week Range | 24.61 - 49.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2022 |
About EMBC
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, ...
Financial Performance
In 2021, Embecta's revenue was $1.17 billion, an increase of 7.27% compared to the previous year's $1.09 billion. Earnings were $415.00 million, a decrease of -3.04%.
Financial StatementsNews
Why Embecta Shares Are Falling Today
Becton Dickinson and Co's (NYSE: BDX) pure-play diabetes spin-off Embecta Corp (NASDAQ: EMBC) has reported Q2 sales of $274.5 million, down 3.4% on a reported basis, down 1.3% on a constant currency bas...
Embecta Corp. Reports Second Quarter and First Six Months of Fiscal Year 2022 Financial Results and Provides Financia...
PARSIPPANY, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from ...
embecta Announces Second Quarter 2022 Earnings Conference Call Information
FRANKLIN LAKES, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ: EMBC) today announced that it will report its financial results for the second quarter of fiscal year 2022 befor...
Becton Dickinson Spinoff Embecta Is a Stock to Watch
Embecta Corp. ( EMBC , Financial) may be new to the public markets, but it is well-established in the diabetes field and now free from the control of Becton, Dickinson and Co. ( BDX , Financial) to impl...
embecta completes spin-off from BD and lists on NASDAQ as a global leader in diabetes care
100-year legacy in insulin delivery